| Nov 5 |
Catalent reports Q1 loss, misses market expectations
|
| Nov 5 |
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
|
| Nov 4 |
Novo Holdings' planned $16.5B acquisition of Catalent gets EU inquiry
|
| Nov 4 |
EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6
|
| Oct 30 |
Catalent to sell New Jersey drug facility to Ardena
|
| Oct 30 |
Backlash builds against Novo’s Catalent takeover
|
| Oct 24 |
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
|
| Oct 23 |
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
|
| Oct 23 |
Update: Market Chatter: Catalent-Novo Holdings Deal Opposed by Roche CEO
|
| Oct 23 |
Market Chatter: Catalent-Novo Holdings Deal Opposed by Roche CEO
|
